|Day's Range||877.30 - 909.70|
|52 Week Range||848.00 - 1,274.70|
|PE Ratio (TTM)||20.16|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||1,258.11|
* Gilead plans to sell Sovaldi in India for $300 a month (Adds detail, background) Approximately 150 million people in the world live with chronic hepatitis C infection, most of them in low and middle-income countries, and the new licences are designed to give many of them access to an otherwise unaffordable drug. As with AIDS 15 years ago, modern drugs are transforming the ability to fight hepatitis C, and Sovaldi has been hailed as a breakthrough in treating the liver-destroying virus. Sovaldi, chemically known as sofosbuvir, is a far more effective and better-tolerated treatment than older injection regimens, but Gilead has come under fire over its U.S.
Cadila Healthcare, Mylan Laboratories Ltd, Sequent Scientific Ltd, Strides Arcolab Ltd and Hetero Drugs Ltd are the others who will now be able to make and sell the Sovaldi generic, the company said in a statement. The companies will be allowed to set their own prices for the generic drug, and will pay a royalty on their earned sales to Gilead, it said.